NCT04125550View on ClinicalTrials.gov

Propofol vs Sevoflurane in Cyanotic Congenital Heart Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

November 1, 2021

Study Completion Date

January 1, 2022

Conditions
Cyanotic Congenital Heart DiseasePediatric HD
Interventions
DRUG

Propofol

2-3 mg/kg propofol will be administered for anesthesia induction. 10 mg/ kg/h propofol infusion will be administered for the maintenance of anesthesia.

DRUG

Sevoflurane

sevoflurane inhalation (2-8%) will be administered for anesthesia induction. 2% sevoflurane inhalation will be administered for the maintenance of anesthesia.

Trial Locations (1)

01330

Cukurova University, Adana

All Listed Sponsors
lead

Cukurova University

OTHER

NCT04125550 - Propofol vs Sevoflurane in Cyanotic Congenital Heart Disease | Biotech Hunter | Biotech Hunter